Menu

Jan 06, 2026
| Eli Lilly and Nimbus Therapeutics Announce Multi‑Year Collaboration to Develop Oral Obesity Therapy arrow_forward

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3759)

Company Market Cap Price
LLY Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
$985.74B
$1063.02
+2.07%
JNJ Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
$492.05B
$205.33
+0.50%
ABBV AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
$388.96B
$223.91
+1.69%
UNH UnitedHealth Group Incorporated
UNH is primarily a health insurer and provides medical benefit plans through UnitedHealthcare.
$309.76B
$350.58
+2.50%
AZN AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
$282.78B
$94.78
+3.90%
MRK Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
$268.36B
$109.05
+1.49%
NVO Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
$248.55B
$56.16
+1.91%
TMO Thermo Fisher Scientific Inc.
Thermo Fisher directly manufactures and sells diagnostic instruments and equipment used in clinical labs.
$230.80B
$621.97
+1.76%
ABT Abbott Laboratories
Abbott's cardiology device portfolio includes leadless pacemakers (AVEIR), MitraClip/TMVR systems and other interventional devices, representing core revenue drivers in Cardiology Devices.
$220.08B
$128.22
+1.40%
ISRG Intuitive Surgical, Inc.
Intuitive Surgical directly manufactures robotic surgical systems and instruments, i.e., core surgical equipment.
$203.03B
$592.97
+4.69%
AMGN Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
$172.66B
$329.68
+2.79%
DHR Danaher Corporation
Danaher directly sells diagnostic equipment/instruments (e.g., Cepheid and Beckman Coulter diagnostics platforms like DxC 500i, DXi 9000).
$168.53B
$236.76
+0.59%
GILD Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
$146.79B
$121.58
+2.77%
← Previous
1 2 3 ... 38
Next →
Showing page 1 of 38 (3759 total stocks)

Loading company comparison...

Loading research report...

ABBV AbbVie Inc.

AbbVie Secures Health Canada Approval for MAVIRET as First 8‑Week Pan‑Genotypic Hepatitis C Treatment

Jan 06, 2026
AMGN Amgen Inc.

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Pipeline

Jan 06, 2026
AZN AstraZeneca PLC

AstraZeneca Announces Strategic AI Partnership with BostonGene to Accelerate Oncology Development

Jan 06, 2026
JNJ Johnson & Johnson

Johnson & Johnson Reports Positive Topline Results for Nipocalimab in Phase 2b JASMINE Study of Systemic Lupus Erythematosus

Jan 06, 2026
LLY Eli Lilly and Company

Eli Lilly and Nimbus Therapeutics Announce Multi‑Year Collaboration to Develop Oral Obesity Therapy

Jan 06, 2026
UNH UnitedHealth Group Incorporated

UnitedHealth Group to Sell Optum UK to TPG for Up to $1.9 B

Jan 06, 2026
LLY Eli Lilly and Company

Eli Lilly Cuts Mounjaro Prices in China Effective Jan 1, 2026

Jan 01, 2026
NVO Novo Nordisk A/S

Novo Nordisk Wins Supreme Court Patent Ruling in China, Securing Semaglutide Rights Ahead of 2026 Expiration

Dec 31, 2025
JNJ Johnson & Johnson

Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics

Dec 30, 2025
NVO Novo Nordisk A/S

Novo Nordisk Slashes Wegovy Prices in China to Counter Rising Generic Competition

Dec 29, 2025
JNJ Johnson & Johnson

Johnson & Johnson Halts Phase 2b Trial of JNJ‑5939 for Moderate to Severe Atopic Dermatitis

Dec 26, 2025
GILD Gilead Sciences, Inc.

Gilead Acquires Repare’s Polθ Inhibitor RP‑3467 for Up to $30 Million

Dec 25, 2025
LLY Eli Lilly and Company

FlyteHealth Launches Direct‑to‑Employer Access for Eli Lilly’s Obesity Drugs, Expanding Market Reach

Dec 24, 2025
AZN AstraZeneca PLC

AstraZeneca’s LATIFY Trial Fails to Meet Primary Overall Survival Endpoint in Advanced NSCLC

Dec 23, 2025
JNJ Johnson & Johnson

Johnson & Johnson Faces $1.56 Billion Talc Verdict in Cherie Craft Case

Dec 23, 2025
NVO Novo Nordisk A/S

Novo Nordisk Receives FDA Approval for First Oral GLP‑1 Weight‑Loss Pill

Dec 23, 2025
ABT Abbott Laboratories

Abbott Secures FDA Approval for Volt Pulsed Field Ablation System, Expanding Its Cardiac Rhythm Portfolio

Dec 22, 2025
AZN AstraZeneca PLC

AstraZeneca Secures Global Exclusive License for Jacobio’s Pan‑KRAS Inhibitor JAB‑23E73

Dec 22, 2025
GILD Gilead Sciences, Inc.

Gilead Exercises Option to License Assembly Biosciences’ Herpes Programs, Expanding Antiviral Portfolio

Dec 22, 2025
AMGN Amgen Inc.

Amgen Joins Nine Pharma Companies in Trump‑Led Drug‑Price Cut Agreement

Dec 20, 2025
GILD Gilead Sciences, Inc.

Gilead Secures U.S. Tariff Exemption and $32 B Investment in Exchange for Drug‑Pricing Commitments

Dec 20, 2025
MRK Merck & Co., Inc.

Merck Enters U.S. Drug‑Price Agreement with Trump Administration, Secures Three‑Year Tariff Exemption

Dec 20, 2025
UNH UnitedHealth Group Incorporated

UnitedHealth Group Unveils Audit Findings and 23 Action Plans to Strengthen Governance

Dec 20, 2025
AZN AstraZeneca PLC

EMA Validates DATROWAY as First‑Line Therapy for Triple‑Negative Breast Cancer

Dec 19, 2025
ABT Abbott Laboratories

Abbott Secures FDA Clearance and CE Mark for New Piccolo Delivery System, Expanding Neonatal PDA Treatment

Dec 18, 2025
JNJ Johnson & Johnson

FDA Approval Expands TRUFILL n‑BCA System to Treat Chronic Subdural Hematoma

Dec 18, 2025
LLY Eli Lilly and Company

Eli Lilly Announces Positive Phase 3 Results for Oral Weight‑Loss Pill Orforglipron

Dec 18, 2025
AZN AstraZeneca PLC

AstraZeneca Wins EU Approval for Saphnelo Subcutaneous Pen, Expanding Lupus Treatment Options

Dec 17, 2025
MRK Merck & Co., Inc.

Merck Announces Positive Topline Results for KEYNOTE‑B15 Trial, Expanding KEYTRUDA® Use in Muscle‑Invasive Bladder Cancer

Dec 17, 2025
AZN AstraZeneca PLC

AstraZeneca Secures FDA Approval for ENHERTU Plus Pertuzumab as First‑Line Treatment for HER2‑Positive Metastatic Breast Cancer

Dec 16, 2025
GILD Gilead Sciences, Inc.

Gilead’s New HIV Regimen Meets Primary Endpoint in Phase 3 Trial

Dec 15, 2025
JNJ Johnson & Johnson

FDA Grants Priority Review Voucher to Johnson & Johnson’s CAR‑T Therapy for Relapsed Multiple Myeloma

Dec 15, 2025
JNJ Johnson & Johnson

Johnson & Johnson Secures FDA Approval for AKEEGA in BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

Dec 13, 2025
NVO Novo Nordisk A/S

Novo Nordisk Launches Ozempic in India, Targeting a $24‑Per‑Week Price Point

Dec 13, 2025
AMGN Amgen Inc.

Amgen Secures FDA Approval for UPLIZNA in Generalized Myasthenia Gravis, Expanding Rare‑Disease Portfolio

Dec 12, 2025
GILD Gilead Sciences, Inc.

Gilead and Arcus End Phase 3 Trial of Domvanalimab Combination in Advanced Stomach and Esophageal Cancer

Dec 12, 2025
LLY Eli Lilly and Company

EMA Approves Eli Lilly’s Mounjaro for Children 10 and Older

Dec 12, 2025
MRK Merck & Co., Inc.

Merck’s WINREVAIR Receives Positive EU CHMP Opinion for Expanded Pulmonary Arterial Hypertension Indication

Dec 12, 2025
NVO Novo Nordisk A/S

EMA Grants Positive Opinion for Novo Nordisk’s 7.2‑mg Wegovy, Expanding EU Obesity Portfolio

Dec 12, 2025
ISRG Intuitive Surgical, Inc.

Intuitive Surgical Secures FDA Clearance for da Vinci SP in High‑Volume General Surgery Procedures

Dec 11, 2025
LLY Eli Lilly and Company

Eli Lilly Announces Landmark Results from Retatrutide Phase 3 TRIUMPH‑4 Trial

Dec 11, 2025
JNJ Johnson & Johnson

Johnson & Johnson Announces Breakthrough Results from TECVAYLI® + DARZALEX FASPRO® in Phase 3 MajesTEC‑3 Study

Dec 10, 2025
LLY Eli Lilly and Company

Eli Lilly Invests $6 Billion in Alabama Plant to Expand Obesity Drug Production

Dec 10, 2025
MRK Merck & Co., Inc.

Formycon and Zydus Announce Exclusive Licensing Deal for Keytruda Biosimilar FYB206 in U.S. and Canada

Dec 10, 2025
LLY Eli Lilly and Company

Eli Lilly Completes $261 Million Acquisition of Adverum Biotechnologies

Dec 09, 2025
UNH UnitedHealth Group Incorporated

West Virginia Files Lawsuit Against UnitedHealth’s Optum Over Opioid Distribution Practices

Dec 09, 2025
ABBV AbbVie Inc.

AbbVie and OSE Shift Early‑Stage Development of ABBV‑230, Retain Future Commercial Rights

Dec 08, 2025
ABT Abbott Laboratories

Abbott Expands Lingo Continuous Glucose Monitor to Android Devices

Dec 08, 2025
AZN AstraZeneca PLC

AstraZeneca Expands Liquid‑Biopsy Access Partnership to China

Dec 08, 2025
JNJ Johnson & Johnson

Johnson & Johnson Announces Landmark Overall‑Survival Benefit for RYBREVANT®/LAZCLUZE® in Asian NSCLC Patients

Dec 08, 2025